US EditionAsthma drug showed positive results in trials for people with nasal polyps
- An asthma drug has shown positive results in trials for treating people with nasal polyps.
- Participants reported significant improvements in symptoms and quality of life during the trials.
- The study's findings suggest potential for broader use of the drug beyond asthma treatment.
- Health experts are optimistic about the drug's potential for wider use in treatment.
27 Articles
27 Articles
Twice-Yearly Biologic Effective Against Nasal Polyps
(MedPage Today) -- SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials showed. Twice-yearly injections cut total nasal polyps score by a mean of 0.7 more than...
Evening Standard
Asthma drug showed positive results in trials for people with nasal polyps
Tezepelumab was first approved for treating asthma in 2021.
Helena Independent Record
POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery
PLGA-Based Strategies for Intranasal and Pulmonary Applications - Pharma Excipients
Abstract Poly(D,L-lactide-co-glycolide) (PLGA) has emerged as a cornerstone in the development of advanced drug delivery systems, particularly for intranasal and pulmonary routes. Its biodegradability, biocompatibility, and adaptability make it an ideal platform for addressing challenges associated with conventional therapies. By enabling sustained and controlled drug release, PLGA formulations reduce dosing frequency, improve patient compliance…
Coverage Details
Bias Distribution
- 72% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
